Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alisertib SCHEMBL855823 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29437869 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29720486 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29750414 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL15263514 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL854553 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL14125416 | 0.98 | AURKA (0.97) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389378 | 0.97 | AURKA (0.94) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389355 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL20214913 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2293 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057044-A | Nanometer liposome delivery system for targeting PLK1/Aurora kinase and application thereof in oral squamous cell carcinoma treatment | 徐州医科大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2026-03-03 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025245045-A1 | METHODS OF TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025215042-A1 | COMBINATIONS OF A CALCIUM HOMEOSTASIS DISRUPTOR WITH A DEATH RECEPTOR 5 AGONIST FOR TREATING CANCER | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2025-10-16 | — | — | WO | claimed |
| EP-3996750-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Oregon Health & Science University (US) | 2022-05-18 | — | — | EP | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| WO-2022090746-A1 | NMT INHIBITORS FOR TREATING SENESCENCE-ASSOCIATED DISEASES OR DISORDERS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| US-20220119399-A1 | COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-04-21 | — | — | US | claimed |
| US-11298422-B2 | Treating tumors with TTFields and an aurora kinase inhibitor | NOVOCURE GMBH (CH) | 2022-04-12 | — | — | US | claimed |
| EP-3976195-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| US-20220073998-A1 | Methods and Compositions For Identifying And Treating Patients With Small Cell Lung Cancer | UNIVERSITY OF UTAH | 2022-03-10 | — | — | US | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| US-20220054496-A1 | MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-02-24 | — | — | US | claimed |